Literature DB >> 14563452

Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome.

A Mérouani1, E Lévy, J-G Mongeau, P Robitaille, M Lambert, E E Delvin.   

Abstract

Hyperlipidemia, an important characteristic of idiopathic nephrotic syndrome in children (NS), is usually observed during the active phase of the disease and disappears with the resolution of the proteinuria. However, persisting lipid anomalies during remission have been reported in a few studies and raise the question of the later development of atherosclerosis. Plasma lipid profiles in 25 children with NS at remission, with or without active prednisone treatment, were compared with those of an age-matched population. The results indicate that plasma total and LDL-cholesterol levels were above the 95(th) percentile for age and sex in 12 of the 25 patients (48%) with 7 of them having apolipoprotein B and triglyceride concentrations above the 95(th) percentile. Moreover, frequently relapsing children were more likely to have abnormal lipid profile during the remission. We conclude that close monitoring of lipid levels during the remission of the NS especially in those with frequent relapses, is necessary to select the high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563452     DOI: 10.1016/s0009-9120(03)00103-6

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  Tissue factor pathway inhibitor in paediatric patients with nephrotic syndrome.

Authors:  Farida Ahmed Farid; Ahmed Abdullah Mohammed; Hanaa Mohammed Afifi; Rania Saleh Beltagi
Journal:  SAJCH       Date:  2011-12

2.  Brachial artery flow-mediated dilatation and carotid intima medial thickness in pediatric nephrotic syndrome: a cross-sectional case-control study.

Authors:  Illaparambath Rahul; Sriram Krishnamurthy; Santhosh Satheesh; Niranjan Biswal; Zachariah Bobby; Subitha Lakshminarayanan
Journal:  Clin Exp Nephrol       Date:  2014-03-18       Impact factor: 2.801

3.  Paraoxonase 1 192 and 55 polymorphisms in nephrotic children.

Authors:  Nese Karaaslan Biyikli; Harika Alpay; Nurdan Yildiz; Bedia Agachan; Arzu Ergen; Umit Zeybek; Nilufer Bozkurt; Turgay Ispir
Journal:  Pediatr Nephrol       Date:  2006-03-26       Impact factor: 3.714

4.  Tissue factor pathway inhibitor in childhood nephrotic syndrome.

Authors:  Mohamed M Al-Mugeiren; Abdel Galil M Abdel Gader; Saud A Al-Rasheed; Abdullah A Al-Salloum
Journal:  Pediatr Nephrol       Date:  2006-03-31       Impact factor: 3.714

5.  The long-term outcome of childhood nephrotic syndrome in Germany: a cross-sectional study.

Authors:  Malik Aydin; Ingo Franke; Lisa Kurylowicz; Rainer Ganschow; Michael Lentze; Mark Born; Rebekka Hagemann
Journal:  Clin Exp Nephrol       Date:  2019-02-05       Impact factor: 2.801

6.  Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients.

Authors:  Yonas Mulat Simachew; Tamara Antonić; Tamara Gojković; Sandra Vladimirov; Marija Mihajlović; Sanja Vujčić; Gordana Miloševski-Lomić; Jelena Vekić; Aleksandra Zeljković; Vesna Spasojević-Kalimanovska; Amira Peco-Antić; Dušan Paripović; Aleksandra Stefanović
Journal:  Biochem Med (Zagreb)       Date:  2022-06-15       Impact factor: 2.515

7.  Paraoxonase Activity and Lipid Profile in Paediatric Nephrotic Syndrome: A Cross-sectional Study.

Authors:  Vijayetha P Patil; Anuradha B Patil; Vidya S Patil; Deepti G Ingleshwar
Journal:  J Clin Diagn Res       Date:  2016-03-01

8.  Atherosclerosis risk factors in young patients formerly treated for idiopathic nephrotic syndrome.

Authors:  Maria H Kniazewska; Anna K Obuchowicz; Tomasz Wielkoszyński; Joanna Zmudzińska-Kitczak; Katarzyna Urban; Marta Marek; Jolanta Witanowska; Karolina Sieroń-Stołtny
Journal:  Pediatr Nephrol       Date:  2008-10-30       Impact factor: 3.714

9.  Candida spp. and gingivitis in children with nephrotic syndrome or type 1 diabetes.

Authors:  Dorota Olczak-Kowalczyk; Beata Pyrżak; Maria Dąbkowska; Małgorzata Pańczyk-Tomaszewska; Grażyna Miszkurka; Izabela Rogozińska; Ewa Swoboda-Kopeć; Dariusz Gozdowski; Angelika Kalińska; Anna Piróg; Małgorzata Mizerska-Wasiak; Maria Roszkowska-Blaim
Journal:  BMC Oral Health       Date:  2015-05-08       Impact factor: 2.757

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.